VX 770 - Ivacaftor | Kalydeco

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 2503

CAS [873054-44-5]

MF C24H28N2O3
MW 392.49

  • Purity: 99%
  • Soluble in DMSO

VX 770

Description

Orally bioavailable CFTR potentiator; FDA-approved drug for clinical application to patients with cystic fibrosis (CF). VX770 enhances spontaneous, ATP-independent activity of WT-CFTR to a similar magnitude as its effects on G551D channels.

KEYWORDS: VX 770 | supplier | CFTR potentiator | Ivacaftor | Kalydeco | VX770 | [873054-44-5] | [1174930-71-2] | Ion Channel | Cystic Fibrosis | CF | FDA-approved | ATP-independent

Order
Size Unit Price Stock
10 mg €125.00 In Stock
50 mg €425.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...